JP2017528158A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017528158A5 JP2017528158A5 JP2017524110A JP2017524110A JP2017528158A5 JP 2017528158 A5 JP2017528158 A5 JP 2017528158A5 JP 2017524110 A JP2017524110 A JP 2017524110A JP 2017524110 A JP2017524110 A JP 2017524110A JP 2017528158 A5 JP2017528158 A5 JP 2017528158A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- lentiviral vector
- vector
- antigen receptor
- chimeric antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020156063A JP7341110B2 (ja) | 2014-07-25 | 2020-09-17 | キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462028889P | 2014-07-25 | 2014-07-25 | |
| US62/028,889 | 2014-07-25 | ||
| US201562155811P | 2015-05-01 | 2015-05-01 | |
| US62/155,811 | 2015-05-01 | ||
| EP15306036 | 2015-06-29 | ||
| EP15306036.3 | 2015-06-29 | ||
| PCT/EP2015/067090 WO2016012623A1 (en) | 2014-07-25 | 2015-07-24 | Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020156063A Division JP7341110B2 (ja) | 2014-07-25 | 2020-09-17 | キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017528158A JP2017528158A (ja) | 2017-09-28 |
| JP2017528158A5 true JP2017528158A5 (https=) | 2018-08-30 |
| JP6940406B2 JP6940406B2 (ja) | 2021-09-29 |
Family
ID=53514131
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017524110A Expired - Fee Related JP6940406B2 (ja) | 2014-07-25 | 2015-07-24 | キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター |
| JP2020156063A Active JP7341110B2 (ja) | 2014-07-25 | 2020-09-17 | キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター |
| JP2023078059A Withdrawn JP2023113656A (ja) | 2014-07-25 | 2023-05-10 | キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020156063A Active JP7341110B2 (ja) | 2014-07-25 | 2020-09-17 | キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター |
| JP2023078059A Withdrawn JP2023113656A (ja) | 2014-07-25 | 2023-05-10 | キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10752668B2 (https=) |
| EP (2) | EP3511413B1 (https=) |
| JP (3) | JP6940406B2 (https=) |
| CN (2) | CN113846062B (https=) |
| CA (1) | CA2956385A1 (https=) |
| WO (1) | WO2016012623A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3011307T3 (en) | 2012-02-23 | 2025-04-07 | Juno Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| EP3365453A2 (en) * | 2015-10-22 | 2018-08-29 | Juno Therapeutics GmbH | Methods, kits, agents and apparatuses for transduction |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| CN108276493B (zh) * | 2016-12-30 | 2023-11-14 | 南京传奇生物科技有限公司 | 一种嵌合抗原受体及其应用 |
| JP7339160B2 (ja) | 2017-04-27 | 2023-09-05 | ジュノ セラピューティクス ゲーエムベーハー | オリゴマー粒子試薬およびその使用方法 |
| EP3618870A4 (en) | 2017-05-01 | 2021-04-21 | The Trustees of The University of Pennsylvania | MONOCLONAL ANTIBODIES AGAINST ALPHA-SYNUCLEIN FIBRILLES |
| EP3697811A1 (en) | 2017-10-20 | 2020-08-26 | Institut Curie | Hook fusion protein for regulating the cellular trafficking of a target protein |
| US20200331975A1 (en) | 2017-10-20 | 2020-10-22 | Institut Curie | Dap10/12 based cars adapted for rush |
| CA3080109A1 (en) | 2017-11-03 | 2019-05-09 | Sorrento Therapeutics, Inc. | Cd38-directed chimeric antigen receptor constructs |
| CA3088933A1 (en) | 2018-01-17 | 2019-08-01 | Aratinga Bio Tnp | Polymer-encapsulated viral vectors for genetic therapy |
| EP3549597A1 (en) * | 2018-04-06 | 2019-10-09 | Heinrich-Heine-Universität Düsseldorf | Synthetic signalling constructs and its use |
| EP3781176A4 (en) * | 2018-04-09 | 2022-05-25 | The Trustees of the University of Pennsylvania | METHODS AND COMPOSITIONS USING A VIRAL VECTOR FOR THE EXPRESSION OF A TRANSGENE AND AN EFFECTOR |
| CA3096458A1 (en) | 2018-04-12 | 2019-10-17 | Umoja Biopharma, Inc. | Viral vectors and packaging cell lines |
| US12516099B2 (en) | 2018-08-09 | 2026-01-06 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
| SG11202104355SA (en) | 2018-10-31 | 2021-05-28 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
| EP3999540A1 (en) | 2019-07-16 | 2022-05-25 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Antibodies having specificity for cd38 and uses thereof |
| WO2021050789A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| GB201914611D0 (en) * | 2019-10-09 | 2019-11-20 | Autolus Ltd | Engineered immune cell |
| CA3154218A1 (en) * | 2019-10-11 | 2021-04-15 | Crystal Mackall | Recombinant polypeptides for regulatable cellular localization |
| CN115484978A (zh) | 2020-03-05 | 2022-12-16 | 尼奥克斯医疗有限公司 | 使用免疫细胞治疗癌症的方法和组合物 |
| EP4208175A4 (en) * | 2020-09-01 | 2025-05-07 | The Trustees of The University of Pennsylvania | IMPROVED GENERATION OF T-CELL TRANSDUCING LENTIVIRAL VECTORS USING A COCAL ENVELOPE |
| WO2022101482A1 (en) | 2020-11-13 | 2022-05-19 | Honing Biosciences | Means and methods for regulating intracellular trafficking of secretory or cell membrane-anchored proteins of interest |
| WO2022229853A1 (en) * | 2021-04-27 | 2022-11-03 | Novartis Ag | Viral vector production system |
| IT202100011576A1 (it) * | 2021-05-06 | 2022-11-06 | Univ Degli Studi Padova | Nuova sequenza promotore per terapia genica |
| JP2024544566A (ja) | 2021-11-15 | 2024-12-03 | セラベクティス | ヒトパピローマウイルス（ｈｐｖ）抗原の発現の為のレンチウイルスベクター、並びにｈｐｖ誘発癌の処置におけるその実施 |
| CN119630795A (zh) * | 2022-05-23 | 2025-03-14 | 通用医疗公司 | 用于免疫细胞crispr筛选的方法和组合物 |
| WO2024023135A1 (en) | 2022-07-27 | 2024-02-01 | Theravectys | Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers |
| US20250025167A1 (en) | 2023-07-21 | 2025-01-23 | Cilag Gmbh International | Methods of operating a surgical instrument or subsystem thereof |
| EP4624494A1 (en) | 2024-03-29 | 2025-10-01 | Institut Curie | Her2 single domain antibody and uses thereof |
| WO2026020171A2 (en) | 2024-07-19 | 2026-01-22 | Aera Therapeutics, Inc. | Chimeric antigen receptor constructs |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| EP1820858B1 (en) | 1991-03-01 | 2009-08-12 | Dyax Corporation | Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| DE4135543A1 (de) | 1991-10-28 | 1993-04-29 | Boehringer Mannheim Gmbh | Rekombinantes core-streptavidin |
| CA2344995A1 (en) * | 1998-10-05 | 2000-04-13 | Ludwig Institute For Cancer Research | Cancer associated antigens and uses therefor |
| DE69941703D1 (de) | 1999-10-11 | 2010-01-07 | Pasteur Institut | Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen |
| US6841359B2 (en) * | 2000-10-31 | 2005-01-11 | The General Hospital Corporation | Streptavidin-binding peptides and uses thereof |
| US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP1390057A4 (en) * | 2001-04-03 | 2005-10-12 | Curagen Corp | ANTIBODIES BINDING TO ANTIGENOUS POLYPEPTIDES, NUCLEIC ACIDS COATING ANTIGENS, AND METHODS OF USE |
| AU2002307625A1 (en) * | 2002-03-08 | 2003-09-22 | Cueros Industrializados Del Bajio | Method of incorporating heat-stable particles into leather |
| US20050032173A1 (en) | 2003-08-05 | 2005-02-10 | Mauricio Rojas | Fusion proteins with a membrane translocating sequence and methods of using same to inhibit an immune response |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US7265205B2 (en) * | 2005-02-11 | 2007-09-04 | Uti Limited Partnership | Monomeric streptavidin muteins |
| DK2005185T3 (da) * | 2006-03-22 | 2011-01-31 | Viral Logic Systems Technology Corp | Fremgangsmåde til identifikation af polypeptidtargets |
| EP2097378B1 (en) | 2006-11-03 | 2012-09-12 | GlaxoSmithKline LLC | Novel seh inhibitors and their use |
| EP2147683A1 (en) * | 2008-07-25 | 2010-01-27 | DKFZ Deutsches Krebsforschungszentrum | Construct and method for the internalization of cargo molecules into a cell |
| CA2765321A1 (en) * | 2009-06-11 | 2010-12-16 | Franck Perez | Methods and kits for regulating intracellular trafficking of a target protein |
| US9233125B2 (en) * | 2010-12-14 | 2016-01-12 | University Of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer |
| NZ713461A (en) * | 2011-04-15 | 2017-02-24 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
| US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| EP2817330B1 (en) * | 2012-02-22 | 2020-07-08 | The Trustees of the University of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| BR122020002986A8 (pt) * | 2012-08-20 | 2023-04-18 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Método e composições para imunoterapia celular |
| AU2013329186B2 (en) * | 2012-10-10 | 2019-02-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| NZ759969A (en) * | 2013-12-20 | 2022-12-23 | Fred Hutchinson Cancer Center | Tagged chimeric effector molecules and receptors thereof |
| GB2592821B (en) * | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
-
2015
- 2015-07-24 CN CN202110939899.3A patent/CN113846062B/zh active Active
- 2015-07-24 EP EP19159129.6A patent/EP3511413B1/en active Active
- 2015-07-24 US US15/327,517 patent/US10752668B2/en active Active
- 2015-07-24 WO PCT/EP2015/067090 patent/WO2016012623A1/en not_active Ceased
- 2015-07-24 CN CN201580051938.9A patent/CN107531800B/zh active Active
- 2015-07-24 CA CA2956385A patent/CA2956385A1/en active Pending
- 2015-07-24 EP EP15742027.4A patent/EP3172228B1/en not_active Not-in-force
- 2015-07-24 JP JP2017524110A patent/JP6940406B2/ja not_active Expired - Fee Related
-
2020
- 2020-07-17 US US16/931,986 patent/US20210009653A1/en not_active Abandoned
- 2020-09-17 JP JP2020156063A patent/JP7341110B2/ja active Active
-
2023
- 2023-05-10 JP JP2023078059A patent/JP2023113656A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017528158A5 (https=) | ||
| JP2016505635A5 (https=) | ||
| JP2017537622A5 (https=) | ||
| Cook et al. | HTLV-1: persistence and pathogenesis | |
| JP6816031B2 (ja) | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 | |
| JP2019527055A5 (https=) | ||
| JP2020074776A5 (https=) | ||
| JP2016512557A5 (ja) | 二重特異性分子及びそれを用いた方法 | |
| JP2015505299A5 (https=) | ||
| EP4609876A3 (en) | Anti-human papillomavirus 16 e7 t cell receptors | |
| JP2011530309A5 (https=) | ||
| JP2019514373A5 (https=) | ||
| JP2016501535A5 (https=) | ||
| JP2015533841A5 (https=) | ||
| JP2020517635A5 (https=) | ||
| JP2017538401A5 (https=) | ||
| JP2013521789A5 (https=) | ||
| FI3872085T3 (fi) | Esimuotoiset virussekvenssit ja niiden käytöt | |
| RU2015155821A (ru) | Вакцины против малярии | |
| RU2015153250A (ru) | Cd19-специфический химерный антигенный рецептор и его применения | |
| JP2012095652A5 (https=) | ||
| JP2013507907A5 (https=) | ||
| JP2019519529A5 (https=) | ||
| EA202090738A1 (ru) | Способ безопасного индуцирования иммунитета против rsv | |
| RU2015135890A (ru) | Композиция вакцины |